MX2022004071A - Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1. - Google Patents
Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1.Info
- Publication number
- MX2022004071A MX2022004071A MX2022004071A MX2022004071A MX2022004071A MX 2022004071 A MX2022004071 A MX 2022004071A MX 2022004071 A MX2022004071 A MX 2022004071A MX 2022004071 A MX2022004071 A MX 2022004071A MX 2022004071 A MX2022004071 A MX 2022004071A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- glp
- receptor agonist
- agonist effect
- compound
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical group C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 abstract 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical group C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención proporciona un compuesto que tiene la estructura básica mostrada por la fórmula (I) en la cual el anillo de indol y la estructura de pirazolopiridina se unen a través de un sustituyente, una sal de éste o un solvato de ya sea el compuesto o una sal del compuesto, así como un agente preventivo o un agente terapéutico para diabetes mellitus no insulinodependiente (diabetes tipo 2) u obesidad que contiene tal compuesto, sal o solvato como un ingrediente activo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016187605 | 2016-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004071A true MX2022004071A (es) | 2022-05-03 |
Family
ID=61689595
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003488A MX2019003488A (es) | 2016-09-26 | 2017-09-26 | Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1. |
MX2022004071A MX2022004071A (es) | 2016-09-26 | 2019-03-26 | Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003488A MX2019003488A (es) | 2016-09-26 | 2017-09-26 | Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1. |
Country Status (33)
Country | Link |
---|---|
US (3) | US10858356B2 (es) |
EP (3) | EP4349840A2 (es) |
JP (4) | JP6567778B2 (es) |
KR (1) | KR102223227B1 (es) |
CN (1) | CN109790161B (es) |
AU (4) | AU2017330733B2 (es) |
BR (1) | BR112019005322A2 (es) |
CA (1) | CA3038479C (es) |
CL (1) | CL2019000663A1 (es) |
CO (1) | CO2019002595A2 (es) |
CR (1) | CR20190149A (es) |
DK (1) | DK3517538T3 (es) |
DO (1) | DOP2019000074A (es) |
EA (2) | EA037989B1 (es) |
EC (1) | ECSP19020228A (es) |
FI (1) | FI3517538T3 (es) |
IL (2) | IL264945B (es) |
JO (1) | JOP20190060A1 (es) |
LT (1) | LT3517538T (es) |
MA (1) | MA46286A (es) |
MX (2) | MX2019003488A (es) |
PE (1) | PE20190709A1 (es) |
PH (1) | PH12019500659A1 (es) |
PT (1) | PT3517538T (es) |
RS (1) | RS65398B1 (es) |
SA (1) | SA519401409B1 (es) |
SG (1) | SG11201901565VA (es) |
SI (1) | SI3517538T1 (es) |
TN (1) | TN2019000054A1 (es) |
TW (1) | TWI753946B (es) |
UA (1) | UA125586C2 (es) |
WO (1) | WO2018056453A1 (es) |
ZA (1) | ZA201901070B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
WO2019086142A1 (en) * | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
JP7461104B2 (ja) | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
TWI707683B (zh) * | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1受體促效劑及其用途 |
JP7360301B2 (ja) | 2019-11-08 | 2023-10-12 | Kyb株式会社 | 作動流体供給システム |
WO2021155841A1 (en) * | 2020-02-07 | 2021-08-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
WO2021249492A1 (zh) * | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
JP2023534983A (ja) * | 2020-07-20 | 2023-08-15 | エコジーン (シャンハイ) カンパニー リミテッド | テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法 |
CR20230066A (es) * | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
JP2023539584A (ja) | 2020-09-01 | 2023-09-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
US20230322771A1 (en) * | 2020-09-07 | 2023-10-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
EP4242202A4 (en) | 2020-11-27 | 2024-05-15 | Shenzhen Salubris Pharm Co Ltd | BENZIMIDAZOLE DERIVATIVE, ITS PREPARATION METHOD AND ITS MEDICAL USE |
EP4317142A1 (en) | 2021-03-22 | 2024-02-07 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するglp-1受容体作動薬を含有する医薬組成物 |
TW202317553A (zh) | 2021-06-24 | 2023-05-01 | 中國大陸商杭州中美華東製藥有限公司 | Glp-1受體激動劑及其組合物和用途 |
WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CA3231153A1 (en) | 2021-09-08 | 2023-03-16 | Kosuke Takemoto | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
WO2023138684A1 (en) * | 2022-01-24 | 2023-07-27 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023151574A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
WO2023220109A1 (en) * | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 pharmaceutical compositions |
WO2023220112A1 (en) * | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 tablet compositions |
CN116003403A (zh) * | 2022-11-20 | 2023-04-25 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998438A (en) | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
EA004207B1 (ru) | 1998-04-01 | 2004-02-26 | Янссен Фармацевтика Н.В. | Производные пиридина, ингибирующие фосфодиэстеразу iv |
EP1572113B1 (en) * | 2002-08-26 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
ZA200500782B (en) * | 2002-08-26 | 2007-10-31 | Takeda Pharmaceutical | Calcium receptor modulating compound and use thereof |
DE10360774A1 (de) | 2003-12-23 | 2005-07-28 | Robert Bosch Gmbh | Verfahren zur Herstellung eines Brennstoffeinspritzventils und Brennstoffeinspritzventil |
WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
EA201300152A1 (ru) * | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
CA2716664C (en) * | 2008-03-07 | 2016-10-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds |
ME02340B (me) | 2008-06-10 | 2017-02-20 | Abbvie Inc | Triciklična jedinjenja |
DK2413693T3 (en) * | 2009-03-30 | 2015-11-16 | Vtv Therapeutics Llc | Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof |
EP2452680B1 (en) * | 2009-07-09 | 2019-12-18 | RaQualia Pharma Inc. | Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility |
WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
ES2555167T3 (es) | 2011-07-15 | 2015-12-29 | Janssen Pharmaceuticals, Inc. | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa |
EP2953681B1 (en) * | 2013-02-06 | 2017-03-15 | Boehringer Ingelheim International GmbH | New indanyloxydihydrobenzofuranylacetic acids |
CN103086955B (zh) | 2013-02-19 | 2014-10-15 | 中国医学科学院医药生物技术研究所 | 3-氨基-4-烷氧亚胺基哌啶的制备方法 |
US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
-
2017
- 2017-06-16 JO JOP/2019/0060A patent/JOP20190060A1/ar unknown
- 2017-09-26 LT LTEPPCT/JP2017/034620T patent/LT3517538T/lt unknown
- 2017-09-26 CN CN201780059135.7A patent/CN109790161B/zh active Active
- 2017-09-26 SI SI201731497T patent/SI3517538T1/sl unknown
- 2017-09-26 UA UAA201902662A patent/UA125586C2/uk unknown
- 2017-09-26 BR BR112019005322A patent/BR112019005322A2/pt active Search and Examination
- 2017-09-26 RS RS20240426A patent/RS65398B1/sr unknown
- 2017-09-26 CA CA3038479A patent/CA3038479C/en active Active
- 2017-09-26 EP EP24154118.4A patent/EP4349840A2/en active Pending
- 2017-09-26 EA EA201990518A patent/EA037989B1/ru not_active IP Right Cessation
- 2017-09-26 EP EP17853220.6A patent/EP3517538B1/en active Active
- 2017-09-26 FI FIEP17853220.6T patent/FI3517538T3/fi active
- 2017-09-26 TW TW106132936A patent/TWI753946B/zh active
- 2017-09-26 JP JP2018540344A patent/JP6567778B2/ja active Active
- 2017-09-26 US US15/759,872 patent/US10858356B2/en active Active
- 2017-09-26 SG SG11201901565VA patent/SG11201901565VA/en unknown
- 2017-09-26 PE PE2019000705A patent/PE20190709A1/es unknown
- 2017-09-26 PT PT178532206T patent/PT3517538T/pt unknown
- 2017-09-26 TN TNP/2019/000054A patent/TN2019000054A1/en unknown
- 2017-09-26 DK DK17853220.6T patent/DK3517538T3/da active
- 2017-09-26 EP EP22180270.5A patent/EP4134367A1/en not_active Withdrawn
- 2017-09-26 WO PCT/JP2017/034620 patent/WO2018056453A1/ja active Application Filing
- 2017-09-26 KR KR1020197008190A patent/KR102223227B1/ko active IP Right Grant
- 2017-09-26 AU AU2017330733A patent/AU2017330733B2/en active Active
- 2017-09-26 EA EA202190802A patent/EA202190802A3/ru unknown
- 2017-09-26 MA MA046286A patent/MA46286A/fr unknown
- 2017-09-26 CR CR20190149A patent/CR20190149A/es unknown
- 2017-09-26 MX MX2019003488A patent/MX2019003488A/es unknown
-
2019
- 2019-02-19 ZA ZA2019/01070A patent/ZA201901070B/en unknown
- 2019-02-20 IL IL264945A patent/IL264945B/en unknown
- 2019-03-14 CL CL2019000663A patent/CL2019000663A1/es unknown
- 2019-03-20 CO CONC2019/0002595A patent/CO2019002595A2/es unknown
- 2019-03-21 DO DO2019000074A patent/DOP2019000074A/es unknown
- 2019-03-25 EC ECSENADI201920228A patent/ECSP19020228A/es unknown
- 2019-03-25 SA SA519401409A patent/SA519401409B1/ar unknown
- 2019-03-26 MX MX2022004071A patent/MX2022004071A/es unknown
- 2019-03-26 PH PH12019500659A patent/PH12019500659A1/en unknown
- 2019-07-31 JP JP2019141806A patent/JP6957564B2/ja active Active
-
2020
- 2020-08-26 AU AU2020223687A patent/AU2020223687B2/en active Active
- 2020-10-07 US US17/065,122 patent/US11814381B2/en active Active
-
2021
- 2021-10-06 JP JP2021164974A patent/JP7280929B2/ja active Active
- 2021-10-11 IL IL287166A patent/IL287166A/en unknown
-
2022
- 2022-07-13 AU AU2022205222A patent/AU2022205222B2/en active Active
-
2023
- 2023-05-12 JP JP2023079006A patent/JP2023100963A/ja active Pending
- 2023-08-11 US US18/448,497 patent/US20230382912A1/en active Pending
-
2024
- 2024-03-22 AU AU2024201884A patent/AU2024201884A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004071A (es) | Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1. | |
WO2018136202A3 (en) | Compounds and methods for cdk8 modulation and indications therefor | |
PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
WO2017108723A3 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
CL2013002821A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina; composicion farmaceutica que los comprende; y su uso como antagonista de los receptores tropomiosina (trk) para el tratamiento del dolor. | |
EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
JO3654B1 (ar) | مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) | |
PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
EP3969453A4 (en) | CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENYL)IMIDAZO[1,2-A]PYRIDINE- 3-CARBOXAMIDE | |
EA201991021A1 (ru) | Соединения конденсированных бициклических пиридинов и их применение в качестве модуляторов ampa-рецептора | |
NZ741384A (en) | Dopamine d3 receptor antagonists having a morpholine moiety | |
AR040974A1 (es) | Derivados heterociclicos de isoxazolina fusionados y su uso como antidepresivos | |
TH1901001721A (th) | อนุพันธ์ไพราโซโลไพริดีนที่มีผลที่มีผลของglp-1รีเซพเตอร์อะโกนิสต์ | |
EA202192092A3 (ru) | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение | |
CL2008003932A1 (es) | Compuestos derivados de 2-heteroaroil-imidazo[1,2-a]piridina, moduladores de los receptores nucleares nurr1; compuestos intermediarios; composicion farmaceutica; y uso par el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, osteoporosis, cancer, entre otras. | |
CL2007003602A1 (es) | Procedimiento de preparacion de 7-fluoro-4-[2-[4-(tieno[3,2-c]piridin-4-il)piperazin-1-il]etil]-1,2-dihidroquinolein-1-acetamida; uno de los compuestos intermediarios usados; y el procedimiento de preparacion de dicho intermediario. |